Company intelligence / Profile preview
Dual Therapeutics
South San Francisco, California, United Statesdualitastx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Dualitas has developed a proprietary DualScreen platform that screens 100,000+ unique bispecific combinations to identify synergistic cell-surface proximity mechanisms. Lead programs DTX-102 (autoimmune) and DTX-103 (allergic disease) have demonstrated differentiated preclinical profiles compared to available therapies, with enhanced potency and efficacy beyond competitive inhibition.
- Therapeutic areas
- ImmunologyGastroenterology
- Modalities
- Bispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Dual Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dual Therapeutics.